Anti-BR Recombinant Immunotoxin (DT386-BR(RAGLQFPVG)) (CAT#: BioBet-IT004Z) Datasheet

BR

Peptide-based IT

DT386-BR2 is a 47 KDa fusion protein that contains the first 386 residues of DT fused to the antimicrobial peptide BR2 via a rigid peptide linker (AP) 4. BR2 is derived from bufoin IIb (RAGLQFPVG [RLLR] 3), an effective antibacterial peptide with cell penetration and anti-cancer properties. BR2 has only two terminal RLLR repeats and has the ability to penetrate and kill cancer cells without affecting normal cells. In vitro studies have shown that DT386-BR2 is cytotoxic to HeLa (cervical cancer) and MCF-7 (breast cancer) cells, and has almost no toxicity to HEK 293 and HUVEC cells.

Breast cancer, leukemia, cervical cancer

Immuntoxin; biobetter

DT386-BR(RAGLQFPVG)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.